Tokai is committed to developing novel, proprietary treatment options for patients with prostate cancer and other hormonally-driven diseases. Our lead product candidate, galeterone, is currently being evaluated in an ongoing Phase 2 clinical trial in patients with castration resistant prostate cancer and we are preparing for registration studies.

We continue to evaluate partnership opportunities with pharmaceutical and biotechnology companies that align with our strategic, long-term corporate goals. Interested parties should direct inquiries to